Annals of Oncology 8:169-174, 1997
© 1997 European Society for Medical Oncology
research-article |
High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A ‘GISCAD’ phase III study
Division of Medical Oncology: San Carlo Borromeo Hospital Milan, Italy
Correspondence to: Roberto Labianca, MD Division of Medical Oncology San Carlo Borromeo Hospital via Pio 11, 3 20153 Milan, Italy
BACKGROUND:: Although leucovorin (LV) + 5-fluorouracil (5-FU) is considered the treatment of choice for advanced colorectal cancer in most countries, the optimal schedule of this combination has not yet been established. Low-dose LV appears to be as active as high-dose LV in the daily-times-five regimen, but no randomized study of the levorotatory stereoisomer (6s-LV) given at two different dose levels has been published.
PATIENTS AND METHODS:: Between November 1991 and June 1994, 422 patients (all with measurable disease previously untreated with chemotherapy) were randomized to 6S-LV (100 mg/sqm/i.v.) + 5-FU (370 mg/sqm/15 min i.v. infusion), both administered for 5 days every 28 days (arm A), or to 6S-LV (10 mg/sqm/i.v.) + 5-FU (doses as above), also given for 5 days every 28 days (arm B). The primary endpoint of the study was the comparison of response rates (WHO criteria); the secondary endpoint was the assessment of survival and tolerability. No evaluation of the quality of life or the symptomatic effect of treatment was planned.
RESULTS:: The response rate was 9.3% in arm A (95% CI: 5.4–13.1), with 2 CR and 18 PR, and 10.7% in arm B (95% CI: 6.5–14.9), with 3 CR + 19 PR, without any significant difference (P = 0.78). The median time to progression was eight months in both groups and overall survival was 11 months, with no difference between treatments. Toxicity mainly consisted of gastrointestinal side effects (mucositis and diarrhoea), which were rarely severe (grade 3–4: 5%–10% of patients) and similar in the two groups.
CONCLUSIONS:: In this large-scale multicentre trial, the low and high doses of 6S-LV appeared to be equivalent in terms of the biochemical modulation of 5-FU in advanced colorectal cancer although, for several reasons (including the timing and the strict criteria of response evaluation, the high number of patients with unfavourable prognostic factors, the multi-institutional nature of the study, the dose and modality of 5-FU administration), the response rate was lower than that reported in some of the other published studies. Given the considerable difference in economic cost between the two dosages, the use of high-dose 6S-LV in the daily-times-five regimen is not recommended in clinical practice.
biochemical modulation, colorectal cancer, 5-fluorouracil, high-versus low-dose, L-leucovorin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Aschele, D. Debernardis, R. Bandelloni, S. Cascinu, V. Catalano, P. Giordani, S. Barni, D. Turci, G. Drudi, S. Lonardi, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil Ann. Onc., December 1, 2002; 13(12): 1882 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cascinu, C. Aschele, S. Barni, D. Debernardis, C. Baldo, G. Tunesi, V. Catalano, M. P. Staccioli, A. Brenna, P. Muretto, et al. Thymidylate Synthase Protein Expression in Advanced Colon Cancer: Correlation with the Site of Metastasis and the Clinical Response to Leucovorin-modulated Bolus 5-Fluorouracil Clin. Cancer Res., August 1, 1999; 5(8): 1996 - 1999. [Abstract] [Full Text] [PDF]
|
|